Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Endocrine Gland Neoplasms”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1977

[Selection of patients with breast cancer with regard to endocrine therapy].

Predictive tests assisting in selection of breast cancer patients for endocrine therapy have been reviewed. Information gained from histologic sections, such as degree of the tumor differentiation, degree of elastosis, Barr-body count and the DNA content, are valuable predictors of prognosis and response to endocrine therapy. The length of time between mastectomy and recurrence of metastasis is an important factor in predicting response to ablative endocrine surgery. The presence of various enzymes in the tumor tissue, blood groups, immunologic competence, altered metabolism of tryptophan, urinary excretion of steroids and in vitro hormonal responsiveness of the tumor tissue have not been widely used as predictors of tumor response to endocrine therapy. The determination of hormone receptors in primary or metastatic breast tumors is at present the most reliable test in selecting breast cancer patients for endocrine therapy. Future developments in hormone receptor assay may provide a means of tailoring endocrine therapy to the individual patient.

Adrenal Glands↗
PubMed1979

Spontaneous endocrine tumors in Sprague-Dawley rats.

Spontaneous endocrine tumors were found in 81 of 100 Sprague-Dawley rats (42 males and 39 females) which survived for more than 2 years. Most of these tumors were medullary carcinomas of the thyroid, followed by tumors of the anterior pituitary gland, pheochromocytomas and cortical adenomas of the adrenal gland, and islet cell tumors of the pancreas. Multiple occurrence of these tumors was frequently observed. This study describes the morphology of these spontaneous endocrine tumors.

Adrenal Gland Neoplasms↗
PubMed1979

Short-term tissue culture of human breast cancer: presence of estrogen receptors and 17 beta-estradiol stimulation of RNA synthesis.

The stimulation of RNA synthesis induced by estradiol has been studied on 60 breast cancers in short-term cultures. In the same tumors the estrogen receptor (ER) assay was carried out. In 35% of the cases studied the stimulating effect by estradiol in vitro was observed. The frequency of response to in vitro hormone treatment was higher (42%) in ER+ cancers and lower (25%) in ER- cancers. The specificity of the in vitro test was assessed by the use of tamoxifen.

Breast Neoplasms↗
PubMed1979

[Doctrinal and clinical aspects of cancer of the male breast].

On the base of a recent observation of one case of male mamma carcinoma, the authors examine the generalities and the etiopathogenetic factors of this rare tumor, also on the base of the most recent acquisitions on hormonal receptors. Then they stop on the characteristics of clinical picture, and outline the high frequency of unfavourable events, at the first medical examination already. In the end they outline the elective treatment and the therapy for the recovery of the cases with metastasis and they present the results of the most qualified mondial casuistry.

Adrenal Cortex Hormones↗
PubMed1976

Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms.

A review of the clinical features of spontaneous regression of malignant melanoma was undertaken. Thirty-three patients with total regression of primary melanoma ("primary regressors") and 40 (13 of whom were somewhat doubtful) with regression of metastatic disease were reviewed in detail. These patients appeared to represent a typical age incidence of melanoma but the primary regressors showed an unexpected predominance of male over female patients. A variety of unique clinical features of the histories of the patients were noted, but none appeared to explain the regression with any degree of predictability. Cutaneous metastases constituted the most common site of regression, followed, in order, by lymphatic, pulmonary, and hepatic metastases. About 40% of patients with spontaneous regressions appeared to have "spontaneous cure," which implies that the disease had not relapsed either during a long period of follow-up or until death from some other cause. Mechanisms that possibly relate to spontaneous regression of melanoma fall into the following general categories: immunologic, endocrine, pigment metabolic, intracellular, nutritional, and carcinogenic. Further quantitative studies of patients acutally undergoing spontaneous regression or the development of a model of spontaneous regression may be a key to our understanding of this interesting "experiment of nature."

Adult↗
PubMed2025

Pituitary tumor-transforming gene 1 and endocrine cancers: an up-to-date review through history, current insights and future perspectives.

Pituitary tumor-transforming gene 1 (PTTG1), discovered in 1997 by Pei and Melmed, takes part in cellular replication, cell cycle control, DNA repair mechanisms, organogenesis, metabolism regulation, cellular transformation, and senescence. Its biological actions include protein-protein interactions, modulation of gene transcription, and other than intracellular and autocrine mechanisms, even paracrine activities. For the reasons mentioned above, PTTG1 stands out as a multifaceted regulator of cancer biology; it is involved in genomic and chromosomal instability, local invasiveness, neo-lymphangiogenesis, and metastatic spreading. In solid neoplasms, endocrine neoplasms, although deemed rare, have experienced a significant increase in diagnostic incidence in recent years. Endocrine cancers are still a major challenge in healthcare and research since several questions remain unanswered, even though researchers have made considerable efforts to uncover their causes. Twenty-seven years have passed since PTTG1's discovery, and several works have been published. However, only the tip of the iceberg has been unveiled. Herein, we review current knowledge of PTTG1's action in endocrine cancers, such as pituitary, thyroid, testicular, adrenal, pancreatic, and ovarian.

Humans↗
PubMed1979

Endocrine profile in a patient with familial breast cancer: a case-control study.

Urinary and blood hormonal profiles were studied throughout a monthly cycle in a patient with familial breast cancer. Two comparison cohorts (one high-risk and one low-risk) were studied concurrently. Findings disclosed that our breast cancer-affected patient showed a distinctive hormonal pattern characterized by significant elevation throughout the cycle of plasma estrone, estradiol, and prolactin. Save for a depression in plasma FSH in the early follicular phase, this hormone, as wells as LH and progesterone patterns in our patient, were similar to the comparison cohorts. Urinary estrone and estradiol patterns in our patient were elevated early in the follicular phase. Our patient also showed a depression in urinary estrone, estradiol, and estriol following ovulation, which persisted throughout the luteal phase. Blood and urinary hormone patterns in the high-risk cohort were not demonstrably different from the low-risk cohort, with the exception of plasma prolactin. The results on the latter hormone showed an unexpected significant depression throughout most of the menstrual cycle in this low-risk cohort. We conclude that estrone and estradiol elevations, as clearly evidenced in our breast-cancer-affected patient, may provide clues that ultimately might be used as an etiologic discriminant for breast cancer risk and which may also play a pathogenic role in this disease. Since this involved a single patient, our conclusions must be interpreted cautiously.

Adult↗
PubMed1975

Estrogen receptor assay in human breast cancer.

A Workshop on Receptor Assay in Breast Cancer Tissue at the Fourth International Congress on Hormonal Steroids was held in Mexico City, September 2-7, 1974. This report reviews the various methods of steroid receptor assay in breast cancer discussed at this Workshop.

Breast Neoplasms↗
PubMed1976

Precise selection of breast cancer patients with bone metastasis for endocrine ablation.

To enhance the precision of selection of breast cancer patients with bone metastasis for endocrine ablation, 85 patients underwent a Levodopa test for 4 consecutives days. Assessment of the result of the test was made on the basis of thorough clinical evaluation, x-ray examination, and results of serum and skin tests as well as cancer receptor studies when tissue was available. Results of 23 surgical procedures were as follows: bilateral oophorectomy elicited good clinical response in five patients with positive preoperative Levodopa tests; one negative clinical response followed a negative Levodopa test; bilateral adrenaloophorectomy in nine patients elicited good response in seven who had positive Levodopa tests and negative responses in two patients who had negative Levodopa tests; bilateral adrenalectomy in eight patients elicited good response in five patients with positive Levodopa tests and negative responses in three who had negative Levodopa tests. There were no deaths and there was only one complication after operation. Levodopa testing appears to be an effective means for selection of patients with bone pain from recurrent breast cancer who will benefit from endocrine ablation. When the Levodopa test was negative for bone pain relief, endocrine ablation was of no benefit to the patient.

Adrenalectomy↗